Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19183918 | MODIFIED CELLULOSE AND THE PREPARATION METHOD AND APPLICATION THEREOF | April 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 18438664 | MATERIALS AND METHODS FOR PURIFYING DNA, RNA, AND POLYPEPTIDES | February 2024 | March 2025 | Abandon | 13 | 2 | 0 | Yes | No |
| 18386050 | METHODS OF TREATING HEMATOLOGIC CANCERS | November 2023 | December 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18384183 | CROSS-LINKED MALTODEXTRINS FOR THE ORAL DELIVERY OF BIOLOGICAL ACTIVES | October 2023 | October 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18477609 | TOPICAL COMPOSITIONS DESIGNATED TO MAINTAIN AND/OR RESTORE THE INTEGRITY OF THE MUCOSA AND DAMAGED EPIDERMIS | September 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18374500 | TREATMENT REGIMENS | September 2023 | September 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18283101 | CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS | September 2023 | October 2025 | Allow | 25 | 2 | 1 | No | No |
| 18463658 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | September 2023 | February 2026 | Allow | 30 | 2 | 1 | No | No |
| 18243156 | Compounds and Methods for Modulating GFAP | September 2023 | August 2025 | Allow | 23 | 1 | 0 | No | No |
| 18460637 | APPLICATION OF HYALURONIC ACID IN PREPARING MEDICINES FOR PREVENTING OR TREATING FERROPTOSIS-RELATED DISEASES | September 2023 | December 2024 | Allow | 16 | 4 | 0 | No | No |
| 18459507 | COMPOSITION COMPRISING MANNOSE OLIGOSACCHARIDE AND PROCESS FOR MAKING SAME AND USE THEREOF | September 2023 | June 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18354837 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | July 2023 | May 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18346935 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | July 2023 | April 2025 | Allow | 21 | 2 | 0 | No | No |
| 18336436 | ANTIBODY DRUG CONJUGATES | June 2023 | September 2024 | Allow | 16 | 0 | 0 | No | No |
| 18039035 | COMPOSITION FOR USE IN TREATMENT OF A BIOFILM IN A SUBJECT | May 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18322767 | SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASE | May 2023 | April 2025 | Allow | 23 | 1 | 0 | No | No |
| 18037561 | RED-LIGHT-MEDIATED NUCLEIC ACID ANCHORING-TYPE FLUORESCENT PROBE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | May 2023 | October 2025 | Allow | 29 | 0 | 0 | No | No |
| 18313671 | TREATMENT OF A BACTERIAL VAGINAL INFECTION | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18308842 | C-MANNOSIDE COMPOUNDS USEFUL FOR THE TREATMENT OF URINARY TRACT INFECTIONS | April 2023 | June 2025 | Allow | 26 | 2 | 0 | No | No |
| 18137896 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18301845 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18135609 | Nicotinyl Riboside Compounds and Their Uses | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18299303 | MALTODEXTRIN AND PROCESS OF MAKING SAME | April 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18131727 | METHODS FOR REDUCING THE WEIGHT LOSS OR INCREASING THE WEIGHT OF A FELINE IN NEED THEREOF | April 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18131192 | DIAGNOSTIC DRUG, DIAGNOSTIC METHOD AND DIAGNOSTIC DEVICE FOR PERMEABILITY OF INTESTINAL MUCOSA | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18130212 | SILICON CONTAINING DETECTABLE COMPOUNDS | April 2023 | February 2025 | Allow | 22 | 2 | 0 | No | No |
| 18181467 | METHODS OF TREATMENT AND MAINTENANCE THERAPY FOR BLADDER CANCER USING GEMCITABINE | March 2023 | March 2026 | Allow | 36 | 4 | 0 | Yes | No |
| 18180900 | Nanofibrillated Cellulose Fibers | March 2023 | June 2025 | Allow | 28 | 2 | 1 | No | No |
| 18117759 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | March 2023 | August 2025 | Allow | 29 | 2 | 0 | No | No |
| 18176609 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | March 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18043538 | ONE-STEP KIT-BASED SYNTHESIS OF 2-DEOXY-2-[18F]FLUORO-D-SORBITOL | February 2023 | July 2025 | Allow | 28 | 1 | 0 | No | No |
| 18043377 | THERAPY TO STIMULATE HIPPOCAMPAL NEURAL PROGENITORS AND ADULT NEUROGENESIS | February 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18042703 | WATER-SOLUBLE 1,3-DIPHENYLGUANIDINE (DPG)-BASED SUPRAMOLECULAR INCLUSION COMPLEX AND PREPARATION METHOD AND USE THEREOF | February 2023 | December 2025 | Allow | 34 | 1 | 0 | No | No |
| 18170167 | CONJUGATED OLIGONUCLEOTIDES | February 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18156511 | SELECTIVELY CONTROLLABLE CLEAVABLE LINKERS | January 2023 | August 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18155730 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | January 2023 | February 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18002665 | ANTIVIRAL PHARMACEUTICAL COMPOSITION | December 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18011586 | ADJUVANT WITH TLR4 AGONIST ACTIVITY | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18002232 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18009679 | DEVICE FOR SOLID/LIQUID EXTRACTION BY RADIAL ULTRASONIC IRRADIATION, AND ASSOCIATED EXTRACTION METHOD | December 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18062105 | METHOD FOR PRODUCING A POLYPHENOLIC COMPOSITION FROM BARLEY MALT | December 2022 | October 2024 | Allow | 22 | 1 | 0 | No | No |
| 17926341 | CHEMICAL FUNCTIONALIZATION OF CELLULOSIC MATERIALS WITH DIAZO COMPOUNDS | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17925986 | PHOTOSYNTHETICALLY CONTROLLED SPIRULINA EXTRACTS FOR TREATING THE CYTOKINE STORM SYNDROME | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18056008 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 18055579 | OLIGONUCLEOTIDE SYNTHESIZER | November 2022 | January 2025 | Abandon | 26 | 2 | 0 | No | No |
| 17982213 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | November 2022 | August 2025 | Allow | 33 | 3 | 0 | No | No |
| 17975790 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17970537 | GLYCAN COMPOSITIONS AND METHODS OF USE | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 18046261 | Far-Red Dye Probe Formulations | October 2022 | March 2026 | Allow | 41 | 2 | 1 | No | No |
| 17960966 | COMPOSITIONS AND METHODS THAT ATTENUATE COGNITIVE AGING IN INDIVIDUALS WHO DO NOT HAVE DEMENTIA | October 2022 | February 2025 | Abandon | 28 | 2 | 0 | Yes | No |
| 17916862 | 5-POSITION MODIFIED PYRIMIDINES | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17907714 | TREATMENT OF SEPSIS AND HYPERCYTOKINEMIA | September 2022 | February 2026 | Allow | 41 | 2 | 0 | No | No |
| 17914876 | ANTIVIRAL AGENT | September 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17947716 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | September 2022 | October 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17906374 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | September 2022 | November 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17931491 | METHODS AND COMPOSITIONS TO PREVENT AND TREAT INFLAMMATION AND ALLERGIC REACTIONS | September 2022 | February 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17941835 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | September 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17939896 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | September 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17802485 | Method And Apparatus for Enzymatic Synthesis of Polynucleotides | August 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17852453 | COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17850467 | PROTON ACTIVATED ATOMIC MEDICINE | June 2022 | February 2025 | Allow | 32 | 2 | 1 | No | No |
| 17744255 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | May 2022 | December 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17722513 | CD73 INHIBITORS | April 2022 | January 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17658547 | METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDS | April 2022 | August 2024 | Allow | 28 | 2 | 0 | No | No |
| 17639918 | NOVEL BIS (HYDROXY BENZYLIDENE) CYCLIC KETONE BASED TETRA-AZA CORAND | March 2022 | August 2025 | Allow | 41 | 2 | 0 | No | No |
| 17639063 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | February 2022 | September 2025 | Allow | 42 | 1 | 0 | No | No |
| 17674032 | ANIMAL THERAPEUTIC AND FEED COMPOSITIONS AND METHODS OF USE | February 2022 | January 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17633941 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | February 2022 | May 2025 | Allow | 39 | 1 | 0 | No | No |
| 17633895 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | February 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17597343 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND HIGH PROTEIN FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE | January 2022 | October 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17596130 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING OR PREVENTING KIDNEY DISEASE | December 2021 | September 2025 | Abandon | 46 | 2 | 0 | Yes | No |
| 17615254 | SAPONIN PURIFICATION | November 2021 | August 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17500099 | ANALOGUES OF OLEUROPEIN AND OLEACEIN AND USES THEREOF | October 2021 | February 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17494320 | REGULATION OF DNA SYNTHESIS BY NUCLEOTIDES LINKED TO PROTECTING GROUPS | October 2021 | May 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17598040 | SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM | September 2021 | March 2025 | Abandon | 42 | 4 | 0 | No | No |
| 17458200 | DEVICES AND METHODS FOR SYNTHESIS | August 2021 | September 2025 | Allow | 49 | 5 | 1 | Yes | No |
| 17397216 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | August 2021 | October 2025 | Allow | 50 | 6 | 0 | Yes | No |
| 17367115 | OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | July 2021 | October 2024 | Abandon | 40 | 4 | 0 | No | No |
| 17351169 | Targeting Ligands | June 2021 | December 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17293577 | ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | May 2021 | February 2026 | Abandon | 57 | 1 | 1 | Yes | No |
| 17293370 | COMBINATION OF GOLD COMPLEXES WITH OLAPARIB OR OTHER PARP1/2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER RESISTANT TO SAID PARP1/2 INHIBITORS | May 2021 | January 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17317614 | LOW-DOSE TRIPLE COMBINATION FORMULATION | May 2021 | May 2025 | Abandon | 48 | 4 | 0 | Yes | No |
| 17285233 | GALACTOSIDE INHIBITOR OF GALECTINS | April 2021 | August 2025 | Allow | 52 | 5 | 0 | No | No |
| 17285253 | STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF YEAST-DERIVED POLYSACCHARIDE INDUCING TREG CELL | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17215910 | INDUSTRIAL METHOD FOR SIMULTANEOUSLY PREPARING STEVIA REBAUDIANA CHLOROGENIC ACID AND STEVIOSIDE | March 2021 | March 2026 | Allow | 59 | 9 | 0 | No | No |
| 17278958 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | March 2021 | November 2024 | Allow | 44 | 1 | 0 | No | No |
| 17277230 | Normalization of Nucleic Acid Samples and Compositions for Use in the Same | March 2021 | September 2025 | Abandon | 54 | 4 | 0 | Yes | No |
| 17269182 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ISOLATION | February 2021 | November 2024 | Allow | 45 | 2 | 0 | No | No |
| 17267666 | NOVEL GINSENOSIDE AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | February 2021 | January 2024 | Allow | 36 | 2 | 0 | No | No |
| 17265920 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | February 2021 | March 2026 | Allow | 60 | 6 | 0 | No | No |
| 17265794 | ANTIBIOTIC RESISTANCE-MODIFYING TRICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | February 2021 | May 2025 | Allow | 52 | 4 | 0 | No | No |
| 16972456 | NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION | December 2020 | July 2024 | Allow | 44 | 2 | 0 | No | No |
| 17057164 | METHOD FOR SELECTING POLYNUCLEOTIDES BASED ON THE SIZE IN A GLOBULAR FORM | November 2020 | September 2025 | Allow | 58 | 4 | 0 | Yes | No |
| 17050424 | ABCB5 LIGANDS AND SUBSTRATES | October 2020 | June 2025 | Allow | 56 | 3 | 1 | No | No |
| 17049742 | NUCLEIC ACID ISOLATION AND INHIBITOR REMOVAL FROM COMPLEX SAMPLES | October 2020 | May 2025 | Allow | 54 | 3 | 0 | Yes | No |
| 17045986 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | October 2020 | December 2025 | Abandon | 60 | 4 | 0 | No | Yes |
| 17011880 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | September 2020 | December 2024 | Allow | 52 | 3 | 1 | No | No |
| 16999483 | METHOD OF PRODUCTION | August 2020 | November 2024 | Abandon | 51 | 3 | 0 | No | No |
| 16997255 | METHODS OF PROTECTING AN ORGAN USING TETRAHYDROCURCUMIN AND PHOSPHATIDYLCHOLINE | August 2020 | February 2023 | Abandon | 30 | 4 | 0 | No | Yes |
| 16913590 | TERNARY MIXTURES OF 6'-SL, LNnT and LST c | June 2020 | August 2025 | Abandon | 60 | 3 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OLSON, ANDREA STEFFEL.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OLSON, ANDREA STEFFEL works in Art Unit 1693 and has examined 286 patent applications in our dataset. With an allowance rate of 92.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner OLSON, ANDREA STEFFEL's allowance rate of 92.0% places them in the 77% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by OLSON, ANDREA STEFFEL receive 2.70 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by OLSON, ANDREA STEFFEL is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -2.8% benefit to allowance rate for applications examined by OLSON, ANDREA STEFFEL. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 26.0% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 51.2% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 61.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 51% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.3% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 69.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 26.6% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.